Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.50
- Piotroski Score 3.00
- Grade Buy
- Symbol (VOR)
- Company Vor Biopharma Inc.
- Price $0.70
- Changes Percentage (-0.79%)
- Change -$0.01
- Day Low $0.63
- Day High $0.76
- Year High $3.14
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.77
- Trailing P/E Ratio -0.69
- Forward P/E Ratio -0.69
- P/E Growth -0.69
- Net Income $-117,863,000
Income Statement
Quarterly
Annual
Latest News of VOR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Truth and Reconciliation: BC community demands answers after death of residential school survivor | Watch News Videos Online
The sudden death of residential school survivor Douglas Eustache in B.C. has raised concerns about police handling of cases involving Indigenous Peoples. Calls for a thorough investigation have been m...
By Global News | 13 hours ago -
Atos Shares Rise After Shareholders, Creditors Favor Financial-Rescue Plan
Atos saw a 5.7% rise in shares following approval of a financial rescue plan involving fund injection and debt-to-shares conversion. Despite challenges, the company aims to regain investor trust throu...
By MarketWatch | 15 hours ago -
Is Bakkavor Group plc's (LON:BAKK) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Bakkavor Group's stock has risen by 10% in the past three months, prompting an analysis of its financial indicators. The focus was on Return on Equity (ROE), which measures a company's profitability a...
By Yahoo! Finance | 16 hours ago